
Arena Pharmaceuticals ARNA
Annual report 2021
added 12-16-2023
Arena Pharmaceuticals Total Non Current Liabilities 2011-2026 | ARNA
Annual Total Non Current Liabilities Arena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 52.2 M | 57.7 M | 50.7 M | 59.8 M | 64.7 M | 153 M | 162 M | 177 M | 133 M | 132 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | 50.7 M | 104 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
99.5 M | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Anika Therapeutics
ANIK
|
26.1 M | $ 14.19 | -1.18 % | $ 208 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Aptorum Group Limited
APM
|
2.21 M | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
289 M | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
182 M | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.5 | -8.28 % | $ 383 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
14.7 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
48.9 M | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
97.6 M | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | ||
|
Equillium
EQ
|
8.33 M | $ 1.79 | 2.29 % | $ 62.2 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
8.22 M | $ 2.72 | -3.31 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
635 M | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
Cabaletta Bio
CABA
|
43.9 M | $ 3.2 | -6.71 % | $ 3.74 M | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
264 M | $ 2.93 | -8.44 % | $ 1.05 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
4.86 M | $ 25.74 | 0.94 % | $ 689 M |